414 related articles for article (PubMed ID: 38051891)
21. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
22. A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases.
Singh A; Maheshwari S; Yadav JP; Varshney AP; Singh S; Prajapati BG
Cent Nerv Syst Agents Med Chem; 2024 Mar; ():. PubMed ID: 38646682
[TBL] [Abstract][Full Text] [Related]
23. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease.
Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A
Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322
[TBL] [Abstract][Full Text] [Related]
24. Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer's Disease.
Latina V; Giacovazzo G; Cordella F; Balzamino BO; Micera A; Varano M; Marchetti C; Malerba F; Florio R; Ercole BB; La Regina F; Atlante A; Coccurello R; Di Angelantonio S; Calissano P; Amadoro G
Acta Neuropathol Commun; 2021 Mar; 9(1):38. PubMed ID: 33750467
[TBL] [Abstract][Full Text] [Related]
25. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
[TBL] [Abstract][Full Text] [Related]
26. 14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer's disease.
Abdi G; Jain M; Patil N; Upadhyay B; Vyas N; Dwivedi M; Kaushal RS
Front Mol Biosci; 2024; 11():1286536. PubMed ID: 38375509
[TBL] [Abstract][Full Text] [Related]
27. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Pei JJ; Sjögren M; Winblad B
Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
[TBL] [Abstract][Full Text] [Related]
28. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
30. Dysfunctional microglia and tau pathology in Alzheimer's disease.
Ayyubova G
Rev Neurosci; 2023 Jun; 34(4):443-458. PubMed ID: 36302379
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction.
Carter CJ
Neurochem Int; 2011 Feb; 58(3):301-20. PubMed ID: 21167244
[TBL] [Abstract][Full Text] [Related]
32. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease.
Balmik AA; Chinnathambi S
Cell Commun Signal; 2021 May; 19(1):51. PubMed ID: 33962636
[TBL] [Abstract][Full Text] [Related]
33. Characterization of microtubule-associated protein tau isoforms and Alzheimer's disease-like pathology in normal sheep (Ovis aries): relevance to their potential as a model of Alzheimer's disease.
Davies ES; Morphew RM; Cutress D; Morton AJ; McBride S
Cell Mol Life Sci; 2022 Oct; 79(11):560. PubMed ID: 36269420
[TBL] [Abstract][Full Text] [Related]
34. Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.
Gu JL; Liu F
Curr Med Sci; 2020 Dec; 40(6):1009-1021. PubMed ID: 33428128
[TBL] [Abstract][Full Text] [Related]
35. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
36. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
[TBL] [Abstract][Full Text] [Related]
37. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer's disease.
Ułamek-Kozioł M; Furmaga-Jabłońska W; Januszewski S; Brzozowska J; Sciślewska M; Jabłoński M; Pluta R
Neurochem Res; 2013 Sep; 38(9):1769-73. PubMed ID: 23737325
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
39. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
[TBL] [Abstract][Full Text] [Related]
40. Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest.
Pluta R; Czuczwar SJ
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
